PT3402821T - Anticorpos de ligação a psma e suas utilizações - Google Patents

Anticorpos de ligação a psma e suas utilizações

Info

Publication number
PT3402821T
PT3402821T PT177012903T PT17701290T PT3402821T PT 3402821 T PT3402821 T PT 3402821T PT 177012903 T PT177012903 T PT 177012903T PT 17701290 T PT17701290 T PT 17701290T PT 3402821 T PT3402821 T PT 3402821T
Authority
PT
Portugal
Prior art keywords
binding antibody
psma binding
psma
antibody
binding
Prior art date
Application number
PT177012903T
Other languages
English (en)
Original Assignee
Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Univ Eberhard Karls Tuebingen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, Univ Eberhard Karls Tuebingen filed Critical Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
Publication of PT3402821T publication Critical patent/PT3402821T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT177012903T 2016-01-14 2017-01-16 Anticorpos de ligação a psma e suas utilizações PT3402821T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16151281.9A EP3192810A1 (en) 2016-01-14 2016-01-14 Psma binding antibody and uses thereof

Publications (1)

Publication Number Publication Date
PT3402821T true PT3402821T (pt) 2023-09-26

Family

ID=55349634

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177012903T PT3402821T (pt) 2016-01-14 2017-01-16 Anticorpos de ligação a psma e suas utilizações

Country Status (17)

Country Link
US (2) US11612646B2 (pt)
EP (3) EP3192810A1 (pt)
JP (1) JP6893939B2 (pt)
CN (1) CN108699157B (pt)
AU (2) AU2017207947B9 (pt)
BR (1) BR112018014215A2 (pt)
CA (2) CA3199697A1 (pt)
DK (1) DK3402821T5 (pt)
ES (1) ES2963561T3 (pt)
FI (1) FI3402821T3 (pt)
HU (1) HUE064205T2 (pt)
IL (1) IL260402B2 (pt)
PL (1) PL3402821T3 (pt)
PT (1) PT3402821T (pt)
RU (1) RU2762704C2 (pt)
WO (1) WO2017121905A1 (pt)
ZA (1) ZA201804601B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2794658T1 (sl) * 2011-12-19 2017-05-31 Synimmune Gmbh Bispecifična molekula protitelesa
US11548947B2 (en) * 2018-06-21 2023-01-10 Regeneron Pharmaceuticals, Inc. Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
CA3182445A1 (en) 2020-06-11 2021-12-16 Francisco Leon Methods and compositions for preventing type 1 diabetes
JP2023542257A (ja) 2020-09-16 2023-10-05 アムジェン インコーポレイテッド 癌の治療のために二重特異性ｔ細胞誘導分子の治療用量を投与する方法
CN114349867B (zh) * 2020-10-14 2024-05-28 广东菲鹏制药股份有限公司 融合蛋白及其应用
JP2023551535A (ja) * 2020-12-01 2023-12-08 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｔ細胞がんを治療するための方法および材料
CN112480260B (zh) * 2020-12-09 2022-03-08 福州迈新生物技术开发有限公司 抗psma蛋白单克隆抗体、细胞系及其制备方法和应用
PE20240761A1 (es) * 2021-01-28 2024-04-17 Janssen Biotech Inc Proteinas de union a psma y usos de estas
JP2024517701A (ja) 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 組換え生産タンパク質の低分子量種を低減させる方法
AU2023238724A1 (en) 2022-03-21 2024-09-05 Amgen Inc. Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
TW202405015A (zh) * 2022-04-11 2024-02-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｐｓｍａ和ｃｄ２８的抗原結合分子及其醫藥用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
WO2008119566A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
PT2352763E (pt) * 2008-10-01 2016-06-02 Amgen Res (Munich) Gmbh Anticorpos biespecíficos de cadeia única com especificidade para antigénios-alvo com elevado peso molecular
AU2009322164B2 (en) * 2008-12-05 2014-12-18 Molecular Insight Pharmaceuticals, Inc. Technetium-and rhenium-bis(heteroaryl) complexes and methods of use thereof
SI2794658T1 (sl) 2011-12-19 2017-05-31 Synimmune Gmbh Bispecifična molekula protitelesa
CA2917886A1 (en) * 2013-07-12 2015-01-15 Zymeworks Inc. Bispecific cd3 and cd19 antigen binding constructs
US11161906B2 (en) * 2013-07-25 2021-11-02 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
EP3119902A4 (en) * 2014-03-18 2017-11-29 Aptevo Research and Development LLC Cell line-based redirected t-cell cytotoxicity assay
PT3132247T (pt) 2014-04-16 2021-11-03 Juno Therapeutics Gmbh Métodos, kits e aparelho para ampliar uma população de células
EP2985294A1 (en) * 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation

Also Published As

Publication number Publication date
DK3402821T5 (da) 2024-09-23
US11612646B2 (en) 2023-03-28
CN108699157A (zh) 2018-10-23
US20190022205A1 (en) 2019-01-24
JP2019505589A (ja) 2019-02-28
HUE064205T2 (hu) 2024-02-28
AU2017207947B2 (en) 2023-09-07
AU2017207947B9 (en) 2023-09-21
EP3402821A1 (en) 2018-11-21
CN108699157B (zh) 2022-02-01
US20230132249A1 (en) 2023-04-27
EP3693396A2 (en) 2020-08-12
BR112018014215A2 (pt) 2018-12-26
PL3402821T3 (pl) 2024-03-04
RU2762704C2 (ru) 2021-12-22
JP6893939B2 (ja) 2021-06-23
CA3011098A1 (en) 2017-07-20
DK3402821T3 (da) 2023-11-06
WO2017121905A1 (en) 2017-07-20
RU2018128414A3 (pt) 2020-10-20
ZA201804601B (en) 2019-04-24
EP3402821B1 (en) 2023-08-23
AU2017207947A1 (en) 2018-07-26
ES2963561T3 (es) 2024-03-27
IL260402B2 (en) 2023-12-01
CA3199697A1 (en) 2017-07-20
EP3693396A3 (en) 2020-10-14
IL260402B1 (en) 2023-08-01
RU2018128414A (ru) 2020-02-14
EP3192810A1 (en) 2017-07-19
FI3402821T3 (fi) 2023-10-26
AU2023203041A1 (en) 2023-06-08
IL260402A (pt) 2018-08-30

Similar Documents

Publication Publication Date Title
ZA201808160B (en) Bispecific binding proteins and uses thereof
IL266738A (en) Novel antibodies and their uses
IL275510A (en) Specific antigen-binding molecules-ROR1
HK1258267A1 (zh) 抗前/潛在肌生長抑制素抗體及其用途
IL262095A (en) Anti-pacap antibodies and their use
ZA201804601B (en) Psma binding antibody and uses thereof
ZA201804317B (en) Altered april binding antibodies
ZA201901935B (en) Anti-il-33 antibodies and uses thereof
ZA201701912B (en) Antigen binding proteins that bind cxcr5
ZA201901892B (en) Antibodies that bind interleukin-2 and uses thereof
HK1231497A1 (zh) 表現不同結合特徵的 抗原結合蛋白
IL266049A (en) Antibodies against o1 and their uses
IL264417A (en) Anti-o2 antibodies and their uses
IL266082A (en) Anti-chikv antibodies and their use
EP3439692A4 (en) ANTIBODIES BINDING PLECTIN-1 AND USES THEREOF
ZA201906821B (en) Anti-jagged1 antigen binding proteins
ZA201901862B (en) Modified factor h binding protein
IL267318A (en) link test
GB201617935D0 (en) Binding compound and uses thereof
GB201614627D0 (en) Antigen binding proteins
GB201715149D0 (en) IL-ß binding antibody